However, dedicated cardiovascular outcome trials have not been conducted with pramlintide, and the cardiovascular implications remain secondary to its established glycemic and weight management benefits
As obesity improves, so will insulin resistance, metabolic syndrome, and type 2 diabetes
H.ShokriF.HeidaryM.SadeghifardN.et al
Those requiring multiple antihypertensive agents or experiencing difficulty achieving blood pressure targets despite medication adherence may benefit from the dual approach of weight loss and associated blood pressure effects
This is consistent with anecdotal reports showing the increase in semaglutide ADM use being larger in some metropolitan cities than others, and does not always correlate with high diabetes prevalence (Trilliant Health, 2023)
Often researched in Glucose handling and insulin-sensitivity research, anchored to the Lee 2015 Cell Metabolism paper